News

Bellapart, Judith, Hernández-Mitre, María Patricia, Wu, Xiaolin, Wallis, Steven C., Smith, Melissa-Lassig, Stuart, Janine, Fourie, Cheryl, Livermore, Amelia, and Roberts, Jason A. (2026)

Our CRE RESPOND team is off to China with our Population Pharmacokinetics workshop. Stay tuned for more updates.

Ryan, Rochelle, Jarrett, Paul, Lassig-Smith, Melissa, Wallis, Steven C., van Zundert, Andre, Ordonez, Jenny, Won, Hayoung, Lipman, Jeffrey, Hernandez-Mitre, Maria Patricia, and Roberts, Jason A. (2026).

Vale, Cassandra, Sime, Fekade B., Cotta, Menino O., Eriksson, Lars, Roberts, Jason A, Horvath, Robert, and Abdul-Aziz, Mohd H. (2026).

Ryan, Rochelle, McDonald, Scott, Wallis, Steven C, van Zundert, Andre, Wu, Xiolin, Won, Hayoung, Lipman, Jeffrey, Hernandez-Mitre, Maria Patricia, and Roberts, Jason A. (2026)

The DALI‑2 study (Defining Antibiotic Levels in Intensive care patients) is a major academic achievement and the first mulit-continent pharmacokinetic (PK) study to systematically evaluate antibiotic exposure in critically ill adults and children across a global ICU network.

Mohd H Abdul–Aziz, Vesa Cheng, Fay Burrows, Hergen Buscher, Young-Jae Cho, Amanda Corley, Arne Diehl, Eileen Gilder, Hyung-Sook Kim, Bianca J Levkovich, Sung Yoon Lim, Xin Liu, Shay McGuinness, Jenny Ordonez, Rachael Parke, Vincent Pellegrino, Claire Reynolds, Sam Rudham, Steven C Wallis, Susan A Welch, John F Fraser, Kiran Shekar, Jason A Roberts (2026)

On 14 March CRE RESPOND hosted the 4th annual Brisbane Transplant Infectious Diseases Meeting.

Aim: The aim of this study was to describe fluconazole pharmacokinetics and identify dosing regimens that achieve pharmacokinetic/pharmacodynamic targets in this patient cohort.

The PRAGMATIC trial (PhaRmAcoGenoMics for better treatment of fungAl infecTIons) is funded by the Australian Government’s Medical Research Future Fund (MRFF), PRAGMATIC is the first pharmacogenomic clinical trial focused on improving treatment of invasive fungal infections through genotype‑informed antifungal dosing.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Manuel's experience from her recent visit.

ROAD RCT (Resistant‑Optimised Antimicrobial Dosing in Critically Ill Patients) is a randomised clinical trial that places the Centre at the forefront of global efforts to tackle antimicrobial resistance in intensive care.

Walker, Mikaela M., Li, Yixuan, Roberts, Jason A., and Sime, Fekade B. (2026).

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Haifa's experience from her recent visit.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Marta's experience from her recent visit.

Meet one of CRE RESPOND's PhD students, Rob Oakley!

Optimal dosing of meropenem and piperacillin/tazobactam in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to variable pharmacokinetics. We aimed to develop generalisable optimised dosing recommendations for these antibiotics.

NHMRC Emerging Leadership Fellow

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Louise's experience from her recent visit.

The objective of this First-in-Human Phase 1, double-blind, randomized, placebo-controlled study was to assess the pharmacokinetics (PK), safety, and tolerability of the dual targeting beta-lactamase inhibitor xeruborbactam (QPX7728) in healthy adults.